|1.||Genini, D: 2 articles (10/2001 - 02/2000)|
|2.||Carson, D A: 2 articles (10/2001 - 02/2000)|
|3.||Leoni, L M: 2 articles (10/2001 - 02/2000)|
|4.||Shih, H: 2 articles (10/2001 - 02/2000)|
|5.||Kapoor, Sonia: 1 article (06/2012)|
|6.||Panda, Dulal: 1 article (06/2012)|
|7.||Gupta, Suvroma: 1 article (02/2009)|
|8.||Dasgupta, Dipak: 1 article (02/2009)|
|9.||Das, Lalita: 1 article (02/2009)|
|10.||Bhattacharyya, Bhabatarak: 1 article (02/2009)|
02/02/2000 - "Confluent multidrug-resistant cells (MCF-7/ADR), but not drug-sensitive cancer cells (MCF-7) or normal peripheral blood lymphocytes, underwent apoptotic cell death 8-24 hours after exposure to indanocine, as measured by sequential changes in mitochondrial membrane potential, caspase activity, and DNA fragmentation. "
06/01/2012 - "In this study, we have investigated the role of microtubule dynamics in migration of cancer cells using indanocine, a synthetic small molecule inhibitor of tubulin. "
02/24/2009 - "Indanocine, a synthetic indanone, has shown potential antiproliferative activity against several tumor types. "
10/01/2001 - "Indanocine is a potent tubulin-binding drug that is cytotoxic to multidrug-resistant cancer cell lines. "
02/02/2000 - "The sensitivity of stationary multidrug-resistant cancer cells to indanocine suggests that indanocine and related indanones be considered as lead compounds for the development of chemotherapeutic strategies for drug-resistant malignancies."
|2.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)